Toxins **2021**, 13, 169

Supplementary Materials: Use of AbobotulinumtoxinA for Cosmetic Treatments in the Neck, and Middle and Lower Areas of the Face: A Systematic Review

Hassan Galadari, Ibrahim Galadari, Riekie Smit, Inna Prygova and Alessio Redaelli

Table S1. Summary of patient satisfaction and quality of life outcomes.

| Study | Study Design | Country | Age, Years | Participants, N (n [%] Women, n [%] Men) | Area(s) of Injection. Indication Assessed | Assessment Tool Used | Key Findings |
|---------------------------|------------------------------------|---------|--------------------------|---|--|---------------------------|---|
| Awaida et al. 2018 [1] | Non-randomized controlled trial | Lebanon | Mean (SD): 55.9 (5.8) | 25 (25 [100%] women) | Neck, lower face. Oral commissures, mar ionette lines, jowls, neck volume, platysma bands at rest and at maximal contraction | satisfied: 2 satisfied: 3 | 100% (n = 25) of patients were satisfied with the results after both the micro injections and Nefertiti techniques 88% (n = 22) of patients were willing to repeat the micro injections technique and recommend to a friend of family member 100% (n = 25) of patients were willing to repeat the Nefertiti technique and recommend to a friend of family member When asked about their preferred technique for neck rejuvenation, 72% (n = 18) of patients chose the micro injections technique, 20% (n = 5) preferred the Nefertiti lift and 8% (n = 2) had no preference |

Toxins **2021**, *13*, *169*

| Study | Study Design | Country | Age, Years | Participants, N (n [%] Women, n [%] Men) | Area(s) of Injection. Indication Assessed | Assessment Tool Used | Key Findings |
|---------------------------|------------------------------------|---------|--|---|--|---|---|
| Chang et al. 2018 [2] | Non-randomized controlled trial | USA | Mean: 51.7 Range: 28.8– 72.4 | 32 (32 [100%] women) | Lower face. Perioral rhytids, marionette lines, chin, nasolabial fold, oral commissures, cheeks | ing questions on satisfac- | On average, patients were 22.2% (<i>p</i> = 0.014) more satisfied with their overall facial appearance at day 14 compared with baseline |
| Hexsel et al. 2013 [3] | RCT | Brazil | Mean (SD): 48.3 (7.2) Range: 30.0– 60.0 | 85 (82 [96.5%] women; 3 [3.5%] men) | Mid, lower face. Lower eyelid wrinkles nasal wrinkles, malar wrinkles, perioral wrin kles, marionette lines, gummy/asymmetric smile, cellulitic chin | their level of satisfaction regarding the treatment: totally satisfied, satisfied slightly satisfied, slightly | Scores on the physical domain of the WHOQOL-BREF questionnaire significantly improved between baseline and 4 weeks ($p = 0.036$) Group 2 (who had a total dose of 166–205 U) had significantly higher mean scores for the physical and social relationships domains compared with group 1 (dose 120–165 U) ($p = 0.033$ and $p = 0.012$, respectively) and group 3, (dose 206–250 U) ($p = 0.004$ and $p = 0.025$, respectively). Scores on the psychological domain were also higher in group 2 than in group 3 (p -value not reported) Patient satisfaction 96.4% of all participants were satisfied or totally satisfied at 4 weeks after treatment, 87% at 16 weeks |

Toxins **2021**, *13*, *169*

| Study | Study Design | Country | Age, Years | Participants, N (n [%] Women, n [%] Men) | Area(s) of Injection. Indication Assessed | Assessment Tool Used | Key Findings |
|--------------------------------|------------------------------------|-------------|---|---|---|---|---|
| | | | | | | | after treatment, 84.7% at 20 weeks after treatment, and 95.3% at 24 weeks after treatment |
| Jabbour et al. 2017 [4] | Non-randomized controlled trial | Lebanon | Mean (SD): 54.8 (5.3) | 30 (30 [100%] women) | Lower face, neck. Jowls, platysmal bands at rest and at maximal contraction, marionette lines, neck volume, ora commissures | satisfied; 2, satisfied; 3, | 96.6% of participants were satisfied with results 93.3% rated themselves as improved (Subject Global Aesthetic Improvement scale) 90% would repeat the procedure and 93.3% would recommend to friend or family member |
| Kim et al. 2005 [5] | Non-randomized controlled trial | South Korea | Age ranges: 13–19 years (n = 10) 20–29 years (n = 293) 30–39 years (n = 70) 40–49 years (n = 9) | 383 (355 [92.7%] women; 28 [7.3%] men) | Lower face. Masseter muscle | Satisfaction survey (de- tails not reported in man uscript) | 268 participants (70%) were greatly satisfied with the result and 88 -(23%) were generally satisfied 356 participants (93%) felt positive about the outcome |
| Mazzuco and Hexsel 2010 [6] | Observational study | Brazil | NR | 16 (NR) | Lower face. Gummy smile | | 14 of 16 participants (87.5%) were reasonably satisfied with the results |

Abbreviations: NR, not reported; RCT, randomized controlled trial; SD, standard deviation; WHOQOL-BREF, World Health Organization Quality of Life-Brief Version questionnaire.

Toxins 2021, 13, 169 S4 of S5

Table S2. Searches carried out in: Ovid MEDLINE, all segments, 1946 to present; Embase 1974 to 18 July 2019; and Cochrane (CDSR, DARE, CENTRAL, NHS EED, The HTA database, and ACP Journal Club) 23 August 2019.

| No. | Searches | Type | | |
|-----|---|------------------------|--|--|
| 1 | (dysport or abobotulinumtoxin or abobotulinumtoxinA or abobotulinum or AboBoNT- | AbobotulinumtoxinA | | |
| 1 | A or Azzalure).mp. | terms | | |
| 2 | plastic surgery/ or esthetics/ or esthetic surgery/ or dental care/ or procedures/ | | | |
| | (face or facial or aesthetic or cosmetic or line* or wrinkle* or aging or code bar or na- | | | |
| | solabial folds or drooping nasal or nose or decollete or decolletage or drooping mouth | Surgery terms | | |
| 3 | corner or depressor anguli oris or marionette or dimpled chin or chin or nasal root or | Surgery terms | | |
| | bunny lines or gummy smile or gingival smile or platysma* or neck or nefertiti or mas- | | | |
| | seter hypertrophy or bruxism or sternocleidomastoid).mp. | | | |
| 4 | 1 and (2 or 3) | | | |
| 5 | Clinical trial/ | | | |
| 6 | Randomized controlled trial/ | | | |
| 7 | Randomization/ | | | |
| 8 | Single blind procedure/ | | | |
| 9 | Double blind procedure/ | | | |
| 10 | Crossover procedure/ | | | |
| 11 | Placebo/ | | | |
| 12 | Randomized controlled trial.tw. | | | |
| 13 | Rct.tw. | D 1 1 (11. 1 | | |
| 14 | Random allocation.tw. | Randomized controlled | | |
| 15 | Randomly allocated.tw. | trials | | |
| 16 | Allocated randomly.tw. | | | |
| 17 | (allocated adj2 random).tw. | - - | | |
| 18 | Single blind\$.tw. | | | |
| 19 | Double blind\$.tw. | | | |
| 20 | ((treble or triple) adj blind\$).tw. | - | | |
| 21 | Placebo\$.tw. | • | | |
| 22 | Prospective study/ | | | |
| 23 | or/5-22 | | | |
| 24 | (real world or RWE).mp. | | | |
| 25 | (cohort or observational).mp. | | | |
| 26 | exp Longitudinal Studies/ or longitudinal.mp. | Observational studies | | |
| 27 | exp Retrospective Studies/ | | | |
| 28 | or/24-27 | | | |
| 29 | Case study/ | | | |
| 30 | Case report.tw. | | | |
| 31 | Abstract report/ or letter/ | | | |
| 32 | or/29-31 | Exclusions and Boolean | | |
| 33 | 4 and (23 or 28) | combinations | | |
| 34 | 33 not 32 | | | |
| | limit 34 to (books or chapter or editorial or letter or note or "review" or short survey or | | | |
| 35 | tombstone) | | | |
| 36 | 34 not 35 | | | |

^{*}Anatomical units of the lower third.

Toxins 2021, 13, 169 S5 of S5

| TE 11 CA | T-1: -1 -1:- | | 1 . | .1 | | 1 | • |
|-----------|--------------|----------|----------|-------|------------|-------------|----------|
| I ahla Sa | HIIOIDIIITA | Critoria | 1160d in | thac | victomatic | litoratiiro | POTITION |
| Table 55. | Eligibility | CITICITA | useu III | uic s | vstemane | micrature | TEVIEW. |
| | | | | | | | |

| | Inclusion Criteria | Exclusion Criteria |
|-----------------------|--|--|
| | Patients receiving abobotulinumtoxinA injec- | Patients receiving abobotulinumtoxin |
| Population | tions in the neck or middle or lower areas of | injections for other indications or in |
| | the face for aesthetic purposes | other regions of the face and body |
| Interventions | AbobotulinumtoxinA | OnabotulinumtoxinA |
| interventions | AbobotumtumtoxinA | IncobotulinumtoxinA |
| | Placebo | |
| Comparator | Other neurotoxins | |
| | Cosmetic treatments | |
| | Treatment approaches (treatment guidelines, | |
| | injection practice and technique, injection fre- | |
| | quency) | |
| | Efficacy outcomes (onset and duration of ac- | |
| Outcomes ^a | tion) | No relevant outcomes |
| | Safety outcomes (adverse events) | |
| | Patient outcomes (cosmetic muscle relaxant, | |
| | wrinkle or line assessments, patient satisfac- | |
| | tion, quality of life) | |
| | Observational studies (retrospective, cross- | Case studies or series |
| Ct. da Dada | sectional or prospective studies) ^b | Modeling study |
| Study Design | RCTs | Comment/editorial |
| | Non-randomized controlled trial ^c | Narrative reviews |
| Countries | Not restricted by country or region | |
| Date Restriction | Not restricted by date | |

Abbreviations: RCT, randomized controlled trial. ^a Excludes outcomes for treatment of non-cosmetic conditions such as hemifacial spasm, chronic facial pain, rhinitis, facial dystonia, sialorrhea, synkinesis, masseteric hypertrophy. ^bRelevant observational studies, non-randomized controlled trials and RCTs, which were referenced in reviews identified in the searches, were included. ^c Narrative reviews were included at first screening so that relevant studies referenced in the reviews could be identified. Narrative reviews were excluded at full-text review.

References

- 1. Awaida, C.J.; Jabbour, S.F.; Rayess, Y.A.; El Khoury, J.S.; Kechichian, E.G.; Nasr, M.W. Evaluation of the microbotox technique: an algorithmic approach for lower face and neck rejuvenation and a crossover clinical trial. *Plastic & Reconstructive Surgery* **2018**, 142, 640–649, doi:https://dx.doi.org/10.1097/PRS.0000000000004695.
- 2. Chang, C.S.; Chang, B.L.; Lanni, M.; Wilson, A.J.; Beer, J.; Percec, I. Perioral rejuvenation: a prospective, quantitative dynamic three-dimensional analysis of a dual modality treatment. *Aesthet* **2018**, *38*, 1225–1236, doi:https://dx.doi.org/10.1093/asj/sjy060.
- 3. Hexsel, D.; Brum, C.; Porto, M.D.; Soirefmann, M.; Siega, C.; Schilling-Souza, J.; Rodrigues, T.C. Quality of life and satisfaction of patients after full-face injections of abobotulinum toxin type A: a randomized, phase IV clinical trial. *Journal of Drugs in Dermatology: JDD* **2013**, *12*, 1363–1367.
- Jabbour, S.F.; Kechichian, E.G.; Awaida, C.J.; Tomb, R.R.; Nasr, M.W. Botulinum toxin for neck rejuvenation: assessing efficacy and redefining patient selection. *Plastic & Reconstructive Surgery* 2017, 140, 9e–17e, doi:https://dx.doi.org/10.1097/PRS.0000000000003429.
- 5. Kim, N.H.; Chung, J.H.; Park, R.-H.; Park, J.B. The use of botulinum toxin type A in aesthetic mandibular contouring. *Plastic & Reconstructive Surgery* **2005**, *115*, 919–930, doi:10.1097/01.PRS.0000153236.79775.A0.
- 6. Mazzuco, R.; Hexsel, D. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. *J Am Acad Dermatol* **2010**, *63*, 1042–1051, doi:https://dx.doi.org/10.1016/j.jaad.2010.02.053.